Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome

An overview of systematic reviews

Moustafa A. Gadalla, Robert J. Norman, Chau T. Tay, Danielle S. Hiam, Angela Melder, Jyotsna Pundir, Shakila Thangaratinam, Helena J. Teede, Ben W.J. Mol, Lisa J. Moran

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Polycystic ovary syndrome (PCOS) is a common, complex condition that affects up to 18% of reproductive-aged women, causing reproductive, metabolic and psychological dysfunctions. We performed an overview and appraisal of methodological quality of systematic reviews that assessed medical and surgical treatments for reproductive outcomes in women with PCOS. Databases (MEDLINE, EMBASE, CINAHL PLUS and PROSPERO) were searched on the 15th of September 2017. We included any systematic review that assessed the effect of medical or surgical management of PCOS on reproductive, pregnancy and neonatal outcomes. Eligibility assessment, data extraction and quality assessment by the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool were performed in duplicate. We identified 53 reviews comprising 44 reviews included in this overview; the majority were moderate to high quality. In unselected women with PCOS, letrozole was associated with a higher live birth rate than clomiphene citrate (CC), while CC was better than metformin or placebo. In women with CC-resistant PCOS, gonadotrophins were associated with a higher live birth rate than CC plus metformin, which was better than laparoscopic ovarian drilling (LOD). LOD was associated with lower multiple pregnancy rates than other medical treatments. In women with PCOS undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), the addition of metformin to gonadotrophins resulted in less ovarian hyperstimulation syndrome (OHSS), and higher pregnancy and live birth rates than gonadotrophins alone. Gonadotrophin releasing hormone (GnRH) antagonist was associated with less OHSS, gonadotrophin units and shorter stimulation length than GnRH agonist. Letrozole appears to be a good first line treatment and gonadotrophins, as a second line treatment, for anovulatory women with PCOS. LOD results in lower multiple pregnancy rates. However, due to the heterogeneous nature of the included populations of women with PCOS, further larger scale trials are needed with more precise assessment of treatments according to heterogeneous variants of PCOS.

Original languageEnglish
Pages (from-to)257-270
Number of pages14
JournalInternational Journal of Fertility and Sterility
Volume13
Issue number4
DOIs
Publication statusPublished - Jan 2020

Keywords

  • Infertility
  • Polycystic Ovary Syndrome
  • Review
  • Therapeutics
  • Treatment Outcome

Cite this

Gadalla, Moustafa A. ; Norman, Robert J. ; Tay, Chau T. ; Hiam, Danielle S. ; Melder, Angela ; Pundir, Jyotsna ; Thangaratinam, Shakila ; Teede, Helena J. ; Mol, Ben W.J. ; Moran, Lisa J. / Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome : An overview of systematic reviews. In: International Journal of Fertility and Sterility. 2020 ; Vol. 13, No. 4. pp. 257-270.
@article{acf37a1311c248e8bc27af0b7d33f9bb,
title = "Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews",
abstract = "Polycystic ovary syndrome (PCOS) is a common, complex condition that affects up to 18{\%} of reproductive-aged women, causing reproductive, metabolic and psychological dysfunctions. We performed an overview and appraisal of methodological quality of systematic reviews that assessed medical and surgical treatments for reproductive outcomes in women with PCOS. Databases (MEDLINE, EMBASE, CINAHL PLUS and PROSPERO) were searched on the 15th of September 2017. We included any systematic review that assessed the effect of medical or surgical management of PCOS on reproductive, pregnancy and neonatal outcomes. Eligibility assessment, data extraction and quality assessment by the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool were performed in duplicate. We identified 53 reviews comprising 44 reviews included in this overview; the majority were moderate to high quality. In unselected women with PCOS, letrozole was associated with a higher live birth rate than clomiphene citrate (CC), while CC was better than metformin or placebo. In women with CC-resistant PCOS, gonadotrophins were associated with a higher live birth rate than CC plus metformin, which was better than laparoscopic ovarian drilling (LOD). LOD was associated with lower multiple pregnancy rates than other medical treatments. In women with PCOS undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), the addition of metformin to gonadotrophins resulted in less ovarian hyperstimulation syndrome (OHSS), and higher pregnancy and live birth rates than gonadotrophins alone. Gonadotrophin releasing hormone (GnRH) antagonist was associated with less OHSS, gonadotrophin units and shorter stimulation length than GnRH agonist. Letrozole appears to be a good first line treatment and gonadotrophins, as a second line treatment, for anovulatory women with PCOS. LOD results in lower multiple pregnancy rates. However, due to the heterogeneous nature of the included populations of women with PCOS, further larger scale trials are needed with more precise assessment of treatments according to heterogeneous variants of PCOS.",
keywords = "Infertility, Polycystic Ovary Syndrome, Review, Therapeutics, Treatment Outcome",
author = "Gadalla, {Moustafa A.} and Norman, {Robert J.} and Tay, {Chau T.} and Hiam, {Danielle S.} and Angela Melder and Jyotsna Pundir and Shakila Thangaratinam and Teede, {Helena J.} and Mol, {Ben W.J.} and Moran, {Lisa J.}",
year = "2020",
month = "1",
doi = "10.22074/ijfs.2020.5608",
language = "English",
volume = "13",
pages = "257--270",
journal = "International Journal of Fertility and Sterility",
issn = "2008-076X",
number = "4",

}

Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome : An overview of systematic reviews. / Gadalla, Moustafa A.; Norman, Robert J.; Tay, Chau T.; Hiam, Danielle S.; Melder, Angela; Pundir, Jyotsna; Thangaratinam, Shakila; Teede, Helena J.; Mol, Ben W.J.; Moran, Lisa J.

In: International Journal of Fertility and Sterility, Vol. 13, No. 4, 01.2020, p. 257-270.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome

T2 - An overview of systematic reviews

AU - Gadalla, Moustafa A.

AU - Norman, Robert J.

AU - Tay, Chau T.

AU - Hiam, Danielle S.

AU - Melder, Angela

AU - Pundir, Jyotsna

AU - Thangaratinam, Shakila

AU - Teede, Helena J.

AU - Mol, Ben W.J.

AU - Moran, Lisa J.

PY - 2020/1

Y1 - 2020/1

N2 - Polycystic ovary syndrome (PCOS) is a common, complex condition that affects up to 18% of reproductive-aged women, causing reproductive, metabolic and psychological dysfunctions. We performed an overview and appraisal of methodological quality of systematic reviews that assessed medical and surgical treatments for reproductive outcomes in women with PCOS. Databases (MEDLINE, EMBASE, CINAHL PLUS and PROSPERO) were searched on the 15th of September 2017. We included any systematic review that assessed the effect of medical or surgical management of PCOS on reproductive, pregnancy and neonatal outcomes. Eligibility assessment, data extraction and quality assessment by the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool were performed in duplicate. We identified 53 reviews comprising 44 reviews included in this overview; the majority were moderate to high quality. In unselected women with PCOS, letrozole was associated with a higher live birth rate than clomiphene citrate (CC), while CC was better than metformin or placebo. In women with CC-resistant PCOS, gonadotrophins were associated with a higher live birth rate than CC plus metformin, which was better than laparoscopic ovarian drilling (LOD). LOD was associated with lower multiple pregnancy rates than other medical treatments. In women with PCOS undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), the addition of metformin to gonadotrophins resulted in less ovarian hyperstimulation syndrome (OHSS), and higher pregnancy and live birth rates than gonadotrophins alone. Gonadotrophin releasing hormone (GnRH) antagonist was associated with less OHSS, gonadotrophin units and shorter stimulation length than GnRH agonist. Letrozole appears to be a good first line treatment and gonadotrophins, as a second line treatment, for anovulatory women with PCOS. LOD results in lower multiple pregnancy rates. However, due to the heterogeneous nature of the included populations of women with PCOS, further larger scale trials are needed with more precise assessment of treatments according to heterogeneous variants of PCOS.

AB - Polycystic ovary syndrome (PCOS) is a common, complex condition that affects up to 18% of reproductive-aged women, causing reproductive, metabolic and psychological dysfunctions. We performed an overview and appraisal of methodological quality of systematic reviews that assessed medical and surgical treatments for reproductive outcomes in women with PCOS. Databases (MEDLINE, EMBASE, CINAHL PLUS and PROSPERO) were searched on the 15th of September 2017. We included any systematic review that assessed the effect of medical or surgical management of PCOS on reproductive, pregnancy and neonatal outcomes. Eligibility assessment, data extraction and quality assessment by the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) tool were performed in duplicate. We identified 53 reviews comprising 44 reviews included in this overview; the majority were moderate to high quality. In unselected women with PCOS, letrozole was associated with a higher live birth rate than clomiphene citrate (CC), while CC was better than metformin or placebo. In women with CC-resistant PCOS, gonadotrophins were associated with a higher live birth rate than CC plus metformin, which was better than laparoscopic ovarian drilling (LOD). LOD was associated with lower multiple pregnancy rates than other medical treatments. In women with PCOS undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI), the addition of metformin to gonadotrophins resulted in less ovarian hyperstimulation syndrome (OHSS), and higher pregnancy and live birth rates than gonadotrophins alone. Gonadotrophin releasing hormone (GnRH) antagonist was associated with less OHSS, gonadotrophin units and shorter stimulation length than GnRH agonist. Letrozole appears to be a good first line treatment and gonadotrophins, as a second line treatment, for anovulatory women with PCOS. LOD results in lower multiple pregnancy rates. However, due to the heterogeneous nature of the included populations of women with PCOS, further larger scale trials are needed with more precise assessment of treatments according to heterogeneous variants of PCOS.

KW - Infertility

KW - Polycystic Ovary Syndrome

KW - Review

KW - Therapeutics

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85074982379&partnerID=8YFLogxK

U2 - 10.22074/ijfs.2020.5608

DO - 10.22074/ijfs.2020.5608

M3 - Review Article

VL - 13

SP - 257

EP - 270

JO - International Journal of Fertility and Sterility

JF - International Journal of Fertility and Sterility

SN - 2008-076X

IS - 4

ER -